Skip to Content
Jump to the top of the page

William Blair Thinking

  • The Multi-Billion Dollar Price Tag of U.S. Rare Earth Independence

    As geopolitical risks rise, the U.S. is pouring capital into building a domestic rare earth supply chain—an effort with massive costs, tight timelines, and significant investment implications.

    Read more
  • Economics Weekly: Wobbles in Private Debt Market

    One topic we have increasingly been receiving questions on over the last few weeks has been private credit, and in this Economics Weekly, we address concerns about whether recent emerging issues in the space pose a systemic threat to the banking system and the wider economy.

    Read more
  • How Continuous Glucose Monitoring Could Expand, Reaching Millions More People with Type 2 Diabetes

    A largely untapped type 2 diabetes population could reshape the future of continuous glucose monitoring, creating a $4 billion opportunity.

    Read more

Our Mission, Vision, and Values

At William Blair, we're committed to our colleagues, our clients, and our communities. Serving our clients starts with the capabilities and collaboration of our team—making our employees our most important asset. When we create an environment where employees perform their best, our delivery for clients will be the best it can be.

Learn more about our mission, vision, and values

Global Community Partners

We are proud of our signature Global Community Partners program, through which employees nominate organizations to receive catalytic financial support and significant volunteerism opportunities every two years.

More about our community partners

Our Latest News

  • William Blair Initiates Coverage of Alamo Group Inc.

    William Blair initiated research coverage of Alamo Group Inc. (ALG $170.15), a manufacturer of specialized equipment for governmental, contractor, industrial, and agricultural end-markets.

    Read more
  • BUNN Has Been Acquired by Ali Group

    William Blair acted as the exclusive financial advisor to BUNN Commercial LP, in connection with its sale to Ali Group.

    Read more
  • BridgeBio Pharma, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of BridgeBio Pharma, Inc. (BBIO $65.36), a commercial-stage biotech company focused on developing medicines for genetic conditions. With this initiation, senior research associate John Boyle, Ph.D. and analyst Myles Minter, Ph.D. have expanded and deepened William Blair’s existing biotechnology coverage.

    Read more

Join Our Team

Finding, attracting, and developing talented people is the foundation of our success. Learn about the promising career opportunities currently available at William Blair.

Search our job openings
Women sitting outside with a laptop

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures